Northern Trust Corp Purchases 45,384 Shares of Evolus, Inc. (NASDAQ:EOLS)

Northern Trust Corp raised its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 9.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 531,167 shares of the company's stock after acquiring an additional 45,384 shares during the quarter. Northern Trust Corp owned approximately 0.84% of Evolus worth $5,864,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. KBC Group NV purchased a new position in shares of Evolus in the 4th quarter valued at approximately $49,000. IFP Advisors Inc raised its position in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Evolus during the 4th quarter valued at about $106,000. Quantbot Technologies LP purchased a new position in Evolus in the fourth quarter worth about $118,000. Finally, Tradition Wealth Management LLC grew its holdings in shares of Evolus by 18.2% during the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock valued at $144,000 after buying an additional 2,000 shares during the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Evolus news, insider Rui Avelar sold 27,904 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the sale, the insider now directly owns 362,467 shares of the company's stock, valued at $4,806,312.42. This represents a 7.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Moatazedi sold 15,787 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $9.87, for a total value of $155,817.69. Following the completion of the transaction, the insider now directly owns 492,832 shares of the company's stock, valued at $4,864,251.84. The trade was a 3.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 86,241 shares of company stock valued at $1,048,666. Company insiders own 5.90% of the company's stock.

Evolus Price Performance

Evolus stock traded up $0.12 during trading on Monday, reaching $9.68. The company had a trading volume of 462,704 shares, compared to its average volume of 694,791. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm's 50-day simple moving average is $10.89 and its 200 day simple moving average is $12.05. The firm has a market capitalization of $624.13 million, a PE ratio of -10.64 and a beta of 1.11.

Wall Street Analysts Forecast Growth

EOLS has been the subject of several research reports. Barclays boosted their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. BTIG Research began coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Evolus in a research note on Thursday, May 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $23.75.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.